External validation of a convolutional neural network for the automatic segmentation of intraprostatic tumor lesions on
PSMA
convolutional neural network
external validation
prostate cancer
segmentation
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
12
2022
accepted:
07
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
State of the art artificial intelligence (AI) models have the potential to become a "one-stop shop" to improve diagnosis and prognosis in several oncological settings. The external validation of AI models on independent cohorts is essential to evaluate their generalization ability, hence their potential utility in clinical practice. In this study we tested on a large, separate cohort a recently proposed state-of-the-art convolutional neural network for the automatic segmentation of intraprostatic cancer lesions on PSMA PET images. Eighty-five biopsy proven prostate cancer patients who underwent When compared to the manual contouring, the AI model yielded a median dice score = 0.74, therefore showing a moderately good performance. Results were robust to the modality used to acquire images (PET/CT or PET/MRI) and to the ground truth labels (no significant difference between the model's performance when compared to reader 1 or reader 2 manual contouring). In conclusion, this AI model could be used to automatically segment intraprostatic cancer lesions for research purposes, as instance to define the volume of interest for radiomics or deep learning analysis. However, more robust performance is needed for the generation of AI-based decision support technologies to be proposed in clinical practice.
Identifiants
pubmed: 36910493
doi: 10.3389/fmed.2023.1133269
pmc: PMC9995820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1133269Informations de copyright
Copyright © 2023 Ghezzo, Mongardi, Bezzi, Samanes Gajate, Preza, Gotuzzo, Baldassi, Jonghi-Lavarini, Neri, Russo, Brembilla, De Cobelli, Scifo, Mapelli and Picchio.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Radiology. 2021 Nov;301(2):379-386
pubmed: 34463555
Eur Urol Oncol. 2022 Aug;5(4):390-400
pubmed: 35715320
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3315-3324
pubmed: 33620559
Eur Urol. 2021 Dec;80(6):682-689
pubmed: 34465492
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):527-538
pubmed: 34255130
Med Phys. 2018 Jun;45(6):2560-2564
pubmed: 29663417
Contrast Media Mol Imaging. 2018 Oct 24;2018:8923028
pubmed: 30473644
Radiology. 2019 Jun;291(3):677-686
pubmed: 30912722
J Nucl Med. 2020 Sep;61(9):1314-1319
pubmed: 32034111
J Nucl Med. 2021 Jun 1;62(6):823-828
pubmed: 33127624
J Urol. 2016 Oct;196(4):1261-7
pubmed: 27220897
Crit Rev Oncol Hematol. 2022 Jan;169:103544
pubmed: 34801699
Cancer Sci. 2020 May;111(5):1452-1460
pubmed: 32133724
Clin Kidney J. 2020 Nov 24;14(1):49-58
pubmed: 33564405
Radiother Oncol. 2019 Dec;141:208-213
pubmed: 31431386
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1795-1805
pubmed: 33341915
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1843-1851
pubmed: 31912257
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):924-932
pubmed: 30890447